Literature DB >> 32165751

Prescribing patterns and comparison of culture versus empiric-based selection of meropenem in cats and dogs in a veterinary teaching hospital (2011-2018).

Lillian M Cousto1, J Scott Weese1, Shane W Bateman1.   

Abstract

The utilization of meropenem in a small animal veterinary teaching hospital over a 7-year period was retrospectively analyzed, and culture (CBD) versus empiric-based decisions (EBD) were compared. Meropenem was infrequently prescribed at a rate of 0.50 prescriptions/1000 admissions in cats and 0.58/1000 in dogs. The most common condition for meropenem prescription in both cats and dogs was septic peritonitis (15/52, 28.8%). Overall 65.4% of meropenem prescriptions were initiated without, or prior to, culture results indicating a need for the drug. Based on retrospective analysis of culture and susceptibility results, only 2.9% of empirical meropenem selections were indicated, while the majority were not indicated (52.9%), or of questionable indication (44.2%). Copyright and/or publishing rights held by the Canadian Veterinary Medical Association.

Entities:  

Year:  2020        PMID: 32165751      PMCID: PMC7020647     

Source DB:  PubMed          Journal:  Can Vet J        ISSN: 0008-5286            Impact factor:   1.008


  29 in total

1.  Positive impact of an emergency department protocol on time to antimicrobial administration in dogs with septic peritonitis.

Authors:  Amanda L Abelson; Gareth J Buckley; Elizabeth A Rozanski
Journal:  J Vet Emerg Crit Care (San Antonio)       Date:  2013-09-09

Review 2.  Public health impact and antimicrobial selection of meticillin-resistant staphylococci in animals.

Authors:  L Guardabassi; J Larsen; J S Weese; P Butaye; A Battisti; J Kluytmans; D H Lloyd; R L Skov
Journal:  J Glob Antimicrob Resist       Date:  2013-05-07       Impact factor: 4.035

3.  Emergence of OXA-48 carbapenemase-producing Escherichia coli and Klebsiella pneumoniae in dogs.

Authors:  Inka Stolle; Ellen Prenger-Berninghoff; Ivonne Stamm; Sandra Scheufen; Esther Hassdenteufel; Sebastian Guenther; Astrid Bethe; Yvonne Pfeifer; Christa Ewers
Journal:  J Antimicrob Chemother       Date:  2013-07-05       Impact factor: 5.790

4.  Pharmacokinetic study of meropenem in healthy beagle dogs receiving intermittent hemodialysis.

Authors:  S Y Byun; J W Jeong; J H Choi; K P Lee; H Y Youn; H J Maeng; K H Song; T S Koo; K W Seo
Journal:  J Vet Pharmacol Ther       Date:  2016-06-15       Impact factor: 1.786

Review 5.  The role of antimicrobials in the treatment of sepsis and critical illness-related bacterial infections: examination of the evidence.

Authors:  Iain Keir; Amy E Dickinson
Journal:  J Vet Emerg Crit Care (San Antonio)       Date:  2015-01-05

6.  Qualitative study of factors associated with antimicrobial usage in seven small animal veterinary practices in the UK.

Authors:  Ana L P Mateus; David C Brodbelt; Nick Barber; Katharina D C Stärk
Journal:  Prev Vet Med       Date:  2014-06-16       Impact factor: 2.670

Review 7.  Extended-spectrum β-lactamase, carbapenemase and AmpC producing Enterobacteriaceae in companion animals.

Authors:  Joseph E Rubin; Johann D D Pitout
Journal:  Vet Microbiol       Date:  2014-02-02       Impact factor: 3.293

8.  Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies.

Authors:  Gopi Patel; Shirish Huprikar; Stephanie H Factor; Stephen G Jenkins; David P Calfee
Journal:  Infect Control Hosp Epidemiol       Date:  2008-12       Impact factor: 3.254

9.  Increasing Incidence of Extended-Spectrum β-Lactamase-Producing Escherichia coli in Community Hospitals throughout the Southeastern United States.

Authors:  Joshua T Thaden; Vance G Fowler; Daniel J Sexton; Deverick J Anderson
Journal:  Infect Control Hosp Epidemiol       Date:  2015-10-13       Impact factor: 3.254

10.  Meropenem antimicrobial stewardship program: clinical, economic, and antibiotic resistance impact.

Authors:  J F García-Rodríguez; B Bardán-García; M F Peña-Rodríguez; H Álvarez-Díaz; A Mariño-Callejo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-10-26       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.